Mixing it up: boosting responses with immunotherapy combinations.

Hiroki Komatsuda, Edward S Sim, Ravindra Uppaluri

Abstract read

In one paragraph

Article in Trends in cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hiroki KomatsudaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan.

Edward S SimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Surgery/Otolaryngology, Brigham and Women's Hospital, Boston, MA, USA; Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA, USA.

Ravindra UppaluriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Surgery/Otolaryngology, Brigham and Women's Hospital, Boston, MA, USA; Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA, USA. Electronic address: ravindra_uppaluri@dfci.harvard.edu.

Funding

Immunotherapeutic responses to neoantigens in head and neck cancerR01DE027736 · NIDCR · DANA-FARBER CANCER INST · PI UPPALURI, RAVINDRA · 2018 to 2022

$2.9M

RESEARCH TRAINING IN OTOLARYNGOLOGYT32DC000020 · NIDCD · MASSACHUSETTS EYE AND EAR INFIRMARY · PI JUNG, DAVID H, SIMONYAN, KRISTINA · 1990 to 2025

$2.4M

NIDCD NIH HHS T32 DC000020NIDCR NIH HHS R01 DE027736

6 · The paper itself

Abstract

Whether combination neoadjuvant immunotherapy can enhance response in patients with head and neck cancer remains unclear. Recently, Li et al. demonstrated improved responses with neoadjuvant anti-PD-1+CTLA-4 or anti-PD-1+LAG-3 compared with anti-PD-1 monotherapy. These combination strategies act via different mechanisms with distinct biomarkers of response, highlighting the potential for personalized neoadjuvant immunotherapy approaches.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsHead and Neck NeoplasmsImmune Checkpoint InhibitorsImmunotherapyBiomarkers, TumorCTLA-4 AntigenHumansLymphocyte Activation Gene 3 ProteinNeoadjuvant TherapyProgrammed Cell Death 1 ReceptorTreatment OutcomeBiomarkers, TumorCTLA-4 AntigenCTLA4 protein, humanImmune Checkpoint InhibitorsLag3 protein, humanLymphocyte Activation Gene 3 ProteinPDCD1 protein, humanProgrammed Cell Death 1 Receptorhead and neck cancerimmune checkpoint inhibitorneoadjuvant immunotherapysingle-cell RNA sequencing

Identifiers

PMID40335428

DOI10.1016/j.trecan.2025.04.013

PMCPMC12158630

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.